• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Signaling Pathways Associated with Prior Cardiovascular Events in Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy. A subset of patients experience major adverse cardiovascular event (MACE) including arrhythmias, stroke, and heart failure. However, molecular mechanisms underlying MACE in HCM are still not well understood. We therefore conducted a multicenter case-control study of patients with HCM comparing those with and without prior history of MACE to identify dysregulated signaling pathways through plasma proteomics profiling.
Source: Journal of Cardiac Failure - August 7, 2023 Category: Cardiology Authors: Charlotte Lee, Lusha W. Liang, Kohei Hasegawa, Mathew S. Maurer, Albree Tower-Rader, Michael A. Fifer, Muredach Reilly, Yuichi J. Shimada Source Type: research

Conditional Survival after HeartMate 3 Implantation: An Analysis of the MOMENTUM 3 Trial
MOMENTUM 3 was a landmark randomized controlled trial of 1028 advanced heart failure patients investigating the outcomes associated with the HeartMate 3 (HM3), a magnetically-levitated centrifugal continuous-flow left ventricular assist device (LVAD) compared to HeartMate II (HMII), an axial continuous-flow LVAD.(1) The primary endpoint was survival-free of disabling stroke and reoperation to replace or remove a malfunctioning device at 6- and 24- months.(1) At both time points, HM3 patients were more likely to successfully achieve the primary endpoint than patients randomized to HMII (6 months: 86.2% vs.
Source: Journal of Cardiac Failure - June 19, 2023 Category: Cardiology Authors: Isabel C. Balachandran, Matthew W. Segar, Nikolaos A. Diakos, Joseph G. Rogers Tags: Research Letter Source Type: research

Conditional Survival After HeartMate 3 Implantation: An Analysis of the MOMENTUM 3 Trial
MOMENTUM 3 was a landmark randomized controlled trial of 1028 patients with advanced heart failure that investigated the outcomes associated with the HeartMate 3 (HM3), a magnetically levitated, centrifugal continuous-flow left ventricular assist device (LVAD) compared to HeartMate II (HMII), an axial continuous-flow LVAD.1 The primary endpoint was survival free of disabling stroke and reoperation to replace or remove a malfunctioning device at 6 and 24 months.1 At both time points, patients with HM3 were more likely to achieve successfully the primary endpoint than patients randomized to HMII (6 months: 86.2% vs 76.8%; 24...
Source: Journal of Cardiac Failure - June 19, 2023 Category: Cardiology Authors: ISABEL C. BALACHANDRAN, MATTHEW W. SEGAR, NIKOLAOS A. DIAKOS, JOSEPH G. ROGERS Tags: Research Letter Source Type: research

Clinical Characteristics And Outcomes Associated With Atrial Fibrillation And Rapid Ventricular Response In Decompensated Heart Failure With Preserved Ejection Fraction
Atrial Fibrillation is the most common dysrhythmia observed worldwide. It is commonly observed in heart failure, with a greater prevalence in Heart Failure with Preserved Ejection Fraction (HFpEF) as opposed to Heart Failure with Reduced Ejection Fraction. Atrial Fibrillation with rapid ventricular response (RVR) may result in increased morbidity and mortality, resulting in worsening heart failure, stroke or death. The clinical characteristics and outcomes of those who present with RVR on presentation in acute decompensated heart failure is not well known.
Source: Journal of Cardiac Failure - April 1, 2023 Category: Cardiology Authors: Sunil Saith, Alexa Kahn, Hannah Every, Hajira Basit, Anuragh Trikha, Jung-eun Ha, Umair Jangda, Ciril Khorolsky, Jose David Chuquin, Tamta Chkhikvadze Tags: 076 Source Type: research

Von Willebrand Factor Activation Assays Predict Bleeding And Other Hemocompatibility-Related Adverse Events In Patients With CF-LVAD.
Bleeding and hemocompatibility-related adverse events (HRAEs - bleeding, neurological event, stroke, arterial thrombosis, pump thrombosis, and death) remain significant in LVAD patients; changes in coagulation homeostasis, mainly due to von Willebrand Factor (vWF) structural and functional changes induced by mechanical support have been considered a major player in these adverse events. However, the specific mechanisms and the clinical correlation between coagulation profile parameters and clinical outcomes are not yet completely clarified.
Source: Journal of Cardiac Failure - April 1, 2023 Category: Cardiology Authors: Bansi Vekaria, Eleonora Avenatti, Aayush Shah, Ju Kim, Rayan Yousefzai, Imad Hussain, Ashrith Guha, Arvind Bhimaraj, Janardhana Gorthi, Jian Chen, Edward A Graviss, Duc T Nguyen, Marcos De Oliveira, Lin-Chiang Philip Chou, Erik Suarez, Thomas E. MacGilliv Tags: 193 Source Type: research

Dietary Inflammatory Score Is Associated With Incident Heart Failure In The Reasons For Geographic And Racial Differences In Stroke Study
Inflammation is a well-established risk factor for heart failure (HF) via processes that lead to atherosclerosis, myocardial fibrosis, and dysfunction. Dietary patterns can influence systemic inflammation, but an association between a “pro-inflammatory diet” and incident HF has not been reported.
Source: Journal of Cardiac Failure - April 1, 2023 Category: Cardiology Authors: Christine Park, Lauren Balkan, Joanna Bryan, James Shikany, Suzanne Judd, Roberd Bostick, Chanel Jonas, Madeline Sterling, Todd Brown, Scott Hummel, Pankaj Arora, Raegan Durant, Elizabeth Jackson, Emily Levitan, Monika Safford, Parag Goyal Tags: 206 Source Type: research

Risk Of Pump Thrombosis With Once Daily Enoxaparin For Anticoagulation Bridging In Patients With Heartmate III
Most centers bridge patients with Left Ventricular Assist Device (LVAD) with heparin drip to avoid thromboembolic complications including stroke and pump thrombosis based on data from HeartMate II. Because of improved hemocompatibility of third generation HeartMateIII (HM3), particularly the decreased risk of in-pump thrombosis, outpatient treatment dose of low molecule weight heparin (LWMH) like Enoxaparin has been used to bridge to warfarin when the INR is subtherapeutic. Once daily dosing has been used in select patients with higher bleeding risk.
Source: Journal of Cardiac Failure - April 1, 2023 Category: Cardiology Authors: Modar Alom, Gurjaspreet Bhattal, Nitin Kabra, David Rawitscher, Amit Alam, Cesar Guerrero-Miranda, Sandra Carey, Timothy George, Aasim Afzal Tags: 180 Source Type: research

Gender Disparities In Patients With Heartmate 3 Left Ventricular Assist Device
Historically, significant gender disparities have existed with patients undergoing 1st and 2nd generation left ventricular assist devices (LVAD) —females tend to have increased mortality and rate of complications such as stroke. In its latest generation, Heartmate 3 (HM3) LVAD has shown significant improvements to prior generations, and significantly lower complications rates including disabling stroke and reoperation. However, gender disp arities with 3rd generation devices such as the HM3 are still unknown.
Source: Journal of Cardiac Failure - April 1, 2023 Category: Cardiology Authors: Ricardo Chia, Michael Sobieraj, Benjamin Rosen, Anastasia Balatsky, Thomas J Price, Vivek Singh, Jason Naftulin, Pedram Kazemian, Kulpreet Barn Tags: 150 Source Type: research

Angiotensin-converting Enzyme Inhibitors (ACE) And Angiotensin Receptor Blockers (ARB) Appear To Attenuate Stroke Risk Over Time In Patients With Left Ventricular Assist Devices
Left ventricular assist devices (LVADs) are used as a bridge to transplant or as a destination therapy for patients with end-stage heart failure. LVADs are associated with increased stroke risk, and many patients on LVAD are treated with ACE/ARBs and vasodilators to keep their mean arterial pressure (MAP) at goal to minimize the risk of stroke. We hypothesized that ACE/ARBs and vasodilators can reduce the 5-year risk of stroke in patients with LVAD.
Source: Journal of Cardiac Failure - April 1, 2023 Category: Cardiology Authors: Jae-Hoon Chung, Jonathan Wright, Mark Boulous, Djhenne Dalmacy, Sakima Smith Tags: 132 Source Type: research

Exertional Cardiac and Pulmonary Vascular Hemodynamics in Patients With Heart Failure With Reduced Ejection Fraction
Exertional dyspnea is a cardinal manifestation of heart failure with reduced ejection fraction (HFrEF). Impairments in the left ventricular (LV) force/tension relationship lead to compromised cardiac output (Qc), such that for any given LV end-diastolic filling pressure, stroke volume (SV) is reduced compared to normal, compromising adequate supply of oxygenated blood to exercising muscle.1,2 As HFrEF progresses, this supply/demand mismatch for oxygen delivery leads to reductions in ventilatory threshold3 and exercise tolerance.
Source: Journal of Cardiac Failure - March 3, 2023 Category: Cardiology Authors: JUSTIN A. EDWARD, HUGH PARKER, ERIC J. ST ÖHR, BARRY J. MCDONNELL, KATIE O'GEAN, MARGARET SCHULTE, JUSTIN S. LAWLEY, WILLIAM K. CORNWELL Source Type: research

Exertional Cardiac and Pulmonary Vascular Hemodynamics Among Patients with Heart Failure with Reduced Ejection Fraction
Exertional dyspnea is a cardinal manifestation of heart failure with reduced ejection fraction (HFrEF). Impairments in the left ventricular (LV) force-tension relationship lead to compromised cardiac output (Qc), such that for any given LV end-diastolic filling pressure, stroke volume (SV) is reduced compared to normal, compromising adequate supply of oxygenated blood to exercising muscle.[1],[2] As HFrEF progresses, this supply-demand mismatch for oxygen delivery leads to reductions in ventilatory threshold[3] and exercise tolerance.
Source: Journal of Cardiac Failure - March 3, 2023 Category: Cardiology Authors: Justin A. Edward, Hugh Parker, Eric J. St öhr, Barry J. McDonnell, Katie O'Gean, Margaret Schulte, Justin S. Lawley, William K. Cornwell Source Type: research

Exertional Cardiac and Pulmonary Vascular Hemodynamics in Patients With Heart Failure With Reduced Ejection Fraction
Exertional dyspnea is a cardinal manifestation of heart failure with reduced ejection fraction (HFrEF). Impairments in the left ventricular (LV) force/tension relationship lead to compromised cardiac output (Qc), such that for any given LV end-diastolic filling pressure, stroke volume (SV) is reduced compared to normal, compromising adequate supply of oxygenated blood to exercising muscle.1,2 As HFrEF progresses, this supply/demand mismatch for oxygen delivery leads to reductions in ventilatory threshold3 and exercise tolerance.
Source: Journal of Cardiac Failure - March 3, 2023 Category: Cardiology Authors: JUSTIN A. EDWARD, HUGH PARKER, ERIC J. ST ÖHR, BARRY J. MCDONNELL, KATIE O'GEAN, MARGARET SCHULTE, JUSTIN S. LAWLEY, WILLIAM K. CORNWELL Source Type: research

Ketone bodies in acute heart failure: fuel for thought
Ketone bodies (KB) might increase in response to physiological situations, usually after glycogen stores have been exhausted (fasting, prolonged exercise) or due to pathological causes (cardiac dysfunction and development of congestion); in patients with acute heart failure, diuresis might reduce KB. Therefore, KB might be a marker of cardiac and hemodynamic stress in heart failure (left panel). Preliminary experimental and human studies suggest that augmentation of KB might have beneficial effects on cardiac hemodynamics and function; for instance, KB might increase heart rate (HR), left ventricular ejection fraction (LVE...
Source: Journal of Cardiac Failure - November 16, 2022 Category: Cardiology Authors: Yosef Manla, William Kuan, Andrew L Clark, John GF Cleland, Pierpaolo Pellicori Source Type: research

Hemodynamic Aberrancies in Left Ventricular Assist Device Associated Heart Failure Syndromes
The advent of the fully magnetically levitated HeartMate 3 LVAD has enabled a marked reduction in hemocompatibility-related adverse events, with a near-elimination of pump thrombosis, and a marked decrease in stroke in LVAD recipients.1,2 As a result, a survival benchmark for LVAD therapy has been established – prolongation of median survival more than 5-years, in patients with advanced heart failure with otherwise severely limited 1-year survival.3
Source: Journal of Cardiac Failure - September 25, 2022 Category: Cardiology Authors: Jacinthe Boulet, Aditi Nayak, Mandeep R. Mehra Tags: JCF Ignite! Source Type: research

Hemodynamic Aberrancies in Left Ventricular Assist Device –Associated Heart Failure Syndromes
The advent of the fully magnetically levitated HeartMate 3 left ventricular assist device (LVAD) has enabled a marked reduction in hemocompatibility-related adverse events, with a near-elimination of pump thrombosis, and a marked decrease in stroke in LVAD recipients.1,2 As a result, a survival benchmark for LVAD therapy has been established —prolongation of the median survival of more than 5 years in patients with advanced heart failure with otherwise severely limited 1-year survival.3
Source: Journal of Cardiac Failure - September 25, 2022 Category: Cardiology Authors: JACINTHE Boulet, ADITI Nayak, MANDEEP R. Mehra Tags: JCF Ignite! Source Type: research

Pages: 1  2  3  4  5  6  7  8  9